Baidu
map

Bone:双膦酸盐类药物治疗骨质疏松症(荟萃分析)

2016-07-24 Mechront 译 MedSci原创

目的:使用网络荟萃分析(NMA)评估双膦酸盐类药物(阿仑膦酸钠、利塞膦酸钠、伊班膦酸钠和唑来膦酸)治疗骨质疏松症的相对疗效。方法:根据PRISMA指南对文献进行系统回顾,使用NMA以确定双膦酸盐类药物对四个骨折结果(脊椎,非脊椎,髋部和手腕)的相对疗效,以及对股骨颈骨密度(BMD)百分比变化的影响。结果:研究共纳入了46项随机对照试验(RCT),27篇RCTs提供骨折数据,35篇RCTs提供了BM

目的:使用网络荟萃分析(NMA)评估双膦酸盐类药物(阿仑膦酸钠、利塞膦酸钠、伊班膦酸钠和唑来膦酸)治疗骨质疏松症的相对疗效。

方法:根据PRISMA指南对文献进行系统回顾,使用NMA以确定双膦酸盐类药物对四个骨折结果(脊椎,非脊椎,髋部和手腕)的相对疗效,以及对股骨颈骨密度(BMD)百分比变化的影响。

结果:研究共纳入了46项随机对照试验(RCT),27篇RCTs提供骨折数据,35篇RCTs提供了BMD数据进行分析。相比安慰剂,唑来膦酸与椎体骨折的最大治疗效果相关(HR 0.41, 95% CrI: 0.28, 0.56),与BMD变化的百分比有关(3.21, 95%: CrI 2.52, 3.86)。利塞膦酸与非脊椎和手腕骨折的最大治疗效果相关(HR 0.72, 95%: CrI 0.53, 0.89;HR 0.77, 95%: CrI 0.44, 1.24)。阿仑膦酸钠与髋部骨折的最大治疗效果有关(HR 0.78, 95% CrI: 0.44, 1.30)。

结论:与安慰剂相比,所有的治疗方法对骨折和股骨颈骨密度都有益处。所有治疗在椎体骨折和股骨颈骨密度的百分比变化的治疗效果上具有统计学意义。两两治疗组比较表明,在骨折方面,没有统计学意义。目前还没有证据表明,不同的治疗效果与性别和年龄有关。

原始出处:

Sanderson J,et al.Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis.Bone. 2016 Aug;89:52-8. doi: 10.1016/j.bone.2016.05.013. Epub 2016 Jun 1.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2016-08-07 apoenzyme
  3. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2017-02-21 venlin
  4. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2016-09-20 wuhai

    很好,学习了,小编给力

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2016-09-17 1e10c84am36(暂无匿称)

    不错哦,会学到很多,喜欢梅斯医学文章

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2016-09-07 李东泽

    很好,不错,以后会多学习

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2016-08-30 ylzr123

    好文,值得学习,赞!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2016-07-26 Eleven17
  9. [GetPortalCommentsPageByObjectIdResponse(id=1836894, encodeId=e2d21836894b3, content=<a href='/topic/show?id=1f188e230c5' target=_blank style='color:#2F92EE;'>#荟萃分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87230, encryptionId=1f188e230c5, topicName=荟萃分析)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b79433, createdName=fangcong, createdTime=Mon Dec 19 10:23:00 CST 2016, time=2016-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915145, encodeId=f4491915145e6, content=<a href='/topic/show?id=05343619cf' target=_blank style='color:#2F92EE;'>#Bone#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3619, encryptionId=05343619cf, topicName=Bone)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7dc7399, createdName=apoenzyme, createdTime=Sun Aug 07 13:23:00 CST 2016, time=2016-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1681318, encodeId=836a1681318df, content=<a href='/topic/show?id=366b8e2299e' target=_blank style='color:#2F92EE;'>#荟萃#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87229, encryptionId=366b8e2299e, topicName=荟萃)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c12d27855367, createdName=venlin, createdTime=Tue Feb 21 11:23:00 CST 2017, time=2017-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=131107, encodeId=b3b613110eab, content=很好,学习了,小编给力, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d2781928203, createdName=wuhai, createdTime=Tue Sep 20 00:08:00 CST 2016, time=2016-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=129376, encodeId=efdf1293e603, content=不错哦,会学到很多,喜欢梅斯医学文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Sep 17 11:40:00 CST 2016, time=2016-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=113283, encodeId=e0711132838b, content=很好,不错,以后会多学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzUn81b5CF5ibVPib8jWI92iciaxmqGHlwruOnK4SVZykd4iahqo1hicklIibyZoxm55X7EM8BW9eX1h1hQ2/0, createdBy=8aa81937526, createdName=李东泽, createdTime=Wed Sep 07 17:19:00 CST 2016, time=2016-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=107224, encodeId=9c0b10e2241d, content=好文,值得学习,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Aug 30 10:34:00 CST 2016, time=2016-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592335, encodeId=fafe15923358b, content=<a href='/topic/show?id=6dc2101853ed' target=_blank style='color:#2F92EE;'>#骨质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101853, encryptionId=6dc2101853ed, topicName=骨质)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1d018108513, createdName=Eleven17, createdTime=Tue Jul 26 12:23:00 CST 2016, time=2016-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=94607, encodeId=87839460e33, content=学习,很详细, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Mon Jul 25 15:22:00 CST 2016, time=2016-07-25, status=1, ipAttribution=)]
    2016-07-25 oo902

    学习,很详细

    0

相关资讯

男性朋友不可错过的骨质疏松症筛查

一项新的研究显示,与接受定期健康筛查的女性不同,男性很容易错过骨质疏松症筛查,即使没有错过,也会很难引起男性的重视。 因此,研究人员发现,男性很难接受骨骼治疗或采取相应的措施保障骨骼健康。 “女性群体会定期接受健康筛查,”Mary Ruppe 博士在医院的新闻发布会上表示,她是休斯顿卫理公会医院内分泌学家。“当女性到了相应的年龄后,她们就会接受初级保健医生和妇产科医师的骨密度筛查。但是对于男性

Nat Med:中国学者揭密骨质疏松和骨肿瘤关键信号通路

4月12日,《自然—医学》在线发表了华东师大刘明耀、罗剑课题组和第二军医大学附属上海长征医院肖建如课题组关于骨质疏松和骨肿瘤治疗的最新发现,该成果的药物开发具有很高的应用价值。据介绍,患有骨质疏松症和骨肿瘤的人群日益增多,但临床上对这些疾病的认识和治疗还存在较大不足。在这项研究中,课题组联合攻关,在原有多项成果基础上展开深入研究,发现LGR4是破骨细胞中最重要细胞分化因子RANKL的新受体,进而深

Nat Commun:研究发现罕见骨质疏松症

来自苏黎世大学和苏黎世大学儿童医院的研究人员发现了第一个遗传性X染色体类型的先天性成骨发育不全症,也称为骨质疏松症。在瑞士约有300到400人,全球大约有五十万人患有骨质疏松症,该病会导致他们的骨头像玻璃一样脆弱。他们的骨形成不仅不好,而且身体组织中其它部位含有的结缔组织也受到了影响。Cecilia Giunta 和 Marianne Rohrbach说,研究人员发现了一种新型骨质疏松症,有两个家

Bone:绝经后女性使用抗抑郁药会增加骨质疏松症风险

骨质疏松症和抑郁症是全球主要的健康问题,那么治疗抑郁症的抗抑郁药和骨骼健康之间有什么关联呢?就此研究者进行了一项研究,探究绝经后妇女使用抗抑郁药物和随时间推移骨质流失间的关系。该研究从OSTPRE试验队列中共纳入了1988名57-67岁女性,分别在1999年和2004年检测参与者的股骨颈骨密度(BMD)。通过国家处方登记册获取参与者抗抑郁药物使用情况。使用多元回归分析在校正人体测量值、医学信息、身

JCEM:绝经后骨质疏松症,双药联合优于单药(DATA-HRpQCT研究)

近期发表在J Clin Endocrinol Metab的研究表明,治疗绝经后骨质疏松症时,联合使用狄诺塞麦和特立帕肽将优于单药治疗,主要表现在臀部和脊柱骨矿物质密度的增加。研究者对94名绝经后骨质疏松症女性进行了一项随机对照试验,探究联合治疗2年对患者骨骼微结构和骨强度的影响。研究者将患者随机分为每日皮下注射特立帕肽20μg组、每6个月皮下注射狄诺塞麦60μg组、两种药物联合治疗组,3组治疗时间

Bone:特立帕肽治疗骨质疏松症+2型糖尿病患者

根据对DANCE试验的事后分析,成人2型糖尿病和骨质疏松症患者进行指定的Forteo治疗,可以降低椎骨骨折发生率,增加骨密度和减少背部疼痛。加利福尼亚大学的Ann V. Schwartz博士和同事分析了4042名骨折高风险的骨质疏松症成年人,其中291例患者有2型糖尿病(平均年龄为69岁)。分析包括了每天至少使用一个剂量的特立帕肽(20 µg/天,皮下注射);影像学诊断由调查人员自行裁决;使用DX

Baidu
map
Baidu
map
Baidu
map